JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences today announced the completion of enrollment for the landmark LUMINATE (Luveniq Uveitis Multicenter Investigation of a New Approach to TrEatment) pivotal clinical trial program, which is investigating the use of LUVENIQ™ (voclosporin; previously designated LX211) as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis. As planned, the three randomized, placebo-controlled, double-masked studies together enrolled a total of about 560 patients at 58 sites in 7 countries.
